Figure 4

Pharmacological blockade of TRPV1 activation with AMG9810 does not affect the LTD induction in the ACC. (A and B) One sample of 64-channel recordings of ACC LTD induction in the presence of AMG9810 (10 μM). A, baseline; B, 1 h after LFS. AMG9810 was bath applied 25 min prior to and during the LFS delivery to the deep layer of the ACC slice. It is clearly illustrated that AMG9810 did not block LFS-induced LTD. Red circles indicate the stimulated channel (Ch. 45). Vertical lines demarcate the different layers in the ACC. (C) Results of one channel (Ch. 46) in the superficial layer of one ACC slice, showing the induction of LTD despite the presence of AMG9810. (D) Summary of averaged data from 6 superficial channels of the same slice. (E) Pooled data for the superficial layer from 6 slices from 6 mice. (F) Pooled data for the superficial layer of the ACC from control group (n = 6 slices/5 mice). (G and H) Summarized data for the deep layer of the ACC from control (H, n = 6 slices/5 mice) and AMG9810-treated (G, n = 6 slices/6 mice) group. Application of AMG9810 did not affect the induction of LTD in any layer of the ACC. Insets in (C, F, G and H): representative fEPSP traces at time points indicated by the numbers in the graph. Horizontal bars in (C-H) denote the period of LFS or drug application as indicated. Calibrations in (A, C, F, G and H): 100 μV, 10 ms. Error bars in (E-H) represent SEM.